Email this article Evaluation of Avatrombopag Efficacy in Chemotherapy-Induced Thrombocytopenia
- Authors: Podenok A.1,2, Manaenkov D.A.3, Manaenkov D.A.3, Falaleevа N.A.3,4, Falaleevа N.A.3,4, Shuvaev V.A.3,4, Shuvaev V.A.3,4, Vovchenko A.A.3,4, Vovchenko A.A.3,4
-
Affiliations:
- A.F. Tsyba Medical Radiological Research Center – Branch of the National Medical Research Center of Radiology, Ministry of Health of the Russian Federation
- 4 Koroleva St., Obninsk, Kaluga Region, 249036, Russian Federation
- A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
- Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
- Issue: Vol 6, No 1 (2026)
- Section: Articles
- Published: 23.09.2026
- URL: https://mdonco.abvpress.ru/jour/article/view/213
- ID: 213
Cite item
Full Text
Abstract
Background. Chemotherapy-induced thrombocytopenia (CIT) is one of the most common and clinically significant complications of anticancer therapy. It limits the ability to maintain planned chemotherapy dose intensity, increases the risk of hemorrhagic complications, and leads to a higher demand for platelet transfusions. Given the limited efficacy and availability of transfusion support, the development of pharmacological approaches for CIT management is of high clinical relevance. Thrombopoietin receptor agonists, including avatrombopag, represent a promising strategy in supportive cancer care.
Objective. To evaluate the efficacy and clinical relevance of prophylactic avatrombopag use in patients with chemotherapy-induced thrombocytopenia.
Materials and Methods. This observational study included 9 patients (4 males and 5 females) with oncological diseases who developed thrombocytopenia (<100×10⁹/L) after a previous chemotherapy cycle. The median age was 52 years (range 27–68). Avatrombopag was administered prophylactically after completion of chemotherapy at a dose of 40 mg/day (20 mg twice daily) for 5 or 10 days, depending on the severity of thrombocytopenia. The following parameters were analyzed: nadir platelet count during the inter-cycle period, incidence of hemorrhagic events, requirement for platelet transfusions, and duration of delay of the subsequent chemotherapy cycle.
Results. During avatrombopag administration, the median nadir platelet count remained unchanged at 10×10⁹/L; however, a marked increase up to 79×10⁹/L was observed in some patients. The incidence of hemorrhagic complications decreased from 55% to 11%. The median number of platelet transfusions was reduced from 3 to 2 units. A significant reduction in chemotherapy delays was observed, with the median delay decreasing from 11 days to 0 days. No avatrombopag-related adverse events were reported.
Conclusion. Prophylactic use of avatrombopag in patients with chemotherapy-induced thrombocytopenia was associated with a reduced incidence of bleeding complications, decreased need for platelet transfusions, and fewer delays in subsequent chemotherapy cycles. Despite the limited sample size, these findings support the clinical value of avatrombopag as a supportive therapy and warrant further prospective studies.
Full Text
About the authors
A. Podenok
A.F. Tsyba Medical Radiological Research Center – Branch of the National Medical Research Center of Radiology, Ministry of Health of the Russian Federation; 4 Koroleva St., Obninsk, Kaluga Region, 249036, Russian Federation
Author for correspondence.
Email: matchamomilla@gmail.com
ORCID iD: 0009-0007-0829-871X
Russian Federation
D. A. Manaenkov
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Email: manaenkov.00@inbox.ru
ORCID iD: 0009-0007-9269-7405
Daniil Arturovich Manaenkov
4 Koroleva St., Obninsk, 249031
Russian FederationD. A. Manaenkov
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Email: manaenkov.00@inbox.ru
ORCID iD: 0009-0007-9269-7405
Daniil Arturovich Manaenkov
4 Koroleva St., Obninsk, 249031
Russian FederationN. A. Falaleevа
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Email: falaleeva-n@mail.ru
ORCID iD: 0000-0002-0023-4216
4 Koroleva St., Obninsk, 249031
1 Studgorodok Territory, Obninsk, 249039
Russian FederationN. A. Falaleevа
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Email: falaleeva-n@mail.ru
ORCID iD: 0000-0002-0023-4216
4 Koroleva St., Obninsk, 249031
1 Studgorodok Territory, Obninsk, 249039
Russian FederationV. A. Shuvaev
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Email: shuvaev77@mail.ru
ORCID iD: 0000-0003-3536-0770
4 Koroleva St., Obninsk, 249031
1 Studgorodok Territory, Obninsk, 249039
Russian FederationV. A. Shuvaev
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Email: shuvaev77@mail.ru
ORCID iD: 0000-0003-3536-0770
4 Koroleva St., Obninsk, 249031
1 Studgorodok Territory, Obninsk, 249039
Russian FederationA. A. Vovchenko
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Email: dr.vovchenkoartem@gmail.com
ORCID iD: 0009-0009-6911-3322
Artem Andreevich Vovchenko
4 Koroleva St., Obninsk, 249031
1 Studgorodok Territory, Obninsk, 249039
Russian FederationA. A. Vovchenko
A.F. Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; Obninsk Institute of Atomic Energy – branch of the National Research Nuclear University “MEPhI”
Email: dr.vovchenkoartem@gmail.com
ORCID iD: 0009-0009-6911-3322
Artem Andreevich Vovchenko
4 Koroleva St., Obninsk, 249031
1 Studgorodok Territory, Obninsk, 249039
Russian FederationReferences
Supplementary files
